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Abstract
Purpose: We examined circulating miRNA expression profiles in plasma of patients with coronary artery disease
(CAD) vs. matched controls, with the aim of identifying novel discriminating biomarkers of Stable (SA) and Unstable
(UA) angina.
Methods: An exploratory analysis of plasmatic expression profile of 367 miRNAs was conducted in a group of SA
and UA patients and control donors, using TaqMan microRNA Arrays. Screening confirmation and expression
analysis were performed by qRT-PCR: all miRNAs found dysregulated were examined in the plasma of troponin-
negative UA (n=19) and SA (n=34) patients and control subjects (n=20), matched for sex, age, and cardiovascular
risk factors. In addition, the expression of 14 known CAD-associated miRNAs was also investigated.
Results: Out of 178 miRNAs consistently detected in plasma samples, 3 showed positive modulation by CAD when
compared to controls: miR-337-5p, miR-433, and miR-485-3p. Further, miR-1, -122, -126, -133a, -133b, and
miR-199a were positively modulated in both UA and SA patients, while miR-337-5p and miR-145 showed a positive
modulation only in SA or UA patients, respectively. ROC curve analyses showed a good diagnostic potential (AUC ≥
0.85) for miR-1, -126, and -483-5p in SA and for miR-1, -126, and -133a in UA patients vs. controls, respectively. No
discriminating AUC values were observed comparing SA vs. UA patients. Hierarchical cluster analysis showed that
the combination of miR-1, -133a, and -126 in UA and of miR-1, -126, and -485-3p in SA correctly classified patients
vs. controls with an efficiency ≥ 87%. No combination of miRNAs was able to reliably discriminate patients with UA
from patients with SA.
Conclusions: This work showed that specific plasmatic miRNA signatures have the potential to accurately
discriminate patients with angiographically documented CAD from matched controls. We failed to identify a plasmatic
miRNA expression pattern capable to differentiate SA from UA patients.
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Introduction
The amount of patients hospitalized in Western countries for
chest pain accounts for several millions each year. In
approximately half of the cases, chest pain is of cardiac origin
[1]. Among these patients, approximately 50% exhibit an
underlying coronary artery disease (CAD), causing either
stable (SA) or unstable (UA) angina pectoris or myocardial
infarction. In the absence of myocardial necrosis leading to
increased plasmatic levels of the cardiac-specific protein
Troponin, there are currently no established circulating
biomarkers that may support the diagnosis of SA or UA.
Notably, missed diagnosis of cardiac ischemia has been
demonstrated to cause an increase in early and mid-term
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mortality [2]. Thus, the identification of novel noninvasive
biomarkers of CAD lacking myocardial necrosis is a compelling
need still under investigation.
MicroRNAs (miRNAs) are ~22 nucleotides long non-coding
RNAs, known to regulate complex biological process by 'fine-
tuning' the translation of specific messenger RNA targets [3].
MiRNAs are pivotal modulators of mammalian cardiovascular
development and disease and can be steadily found in the
systemic circulation of both animals and humans, where they
show a remarkable stability probably due to internalization in
vesicles and binding to circulating proteins and other molecules
[4]. Since their levels may significantly change upon stress,
circulating miRNAs have been proposed as diagnostic
biomarkers in different pathologic conditions (e.g. cancer,
cardiac diseases, liver injury, and hepatitis) [4-6]. Interestingly,
recent reports have suggested the diagnostic potential of
miRNAs in heart diseases, such as heart failure [7] and
myocardial infarction (MI) [8]. In particular, we previously
reported the presence of a distinctive “signature” of 6
circulating miRNAs in patients with ST-Elevation Myocardial
Infarction (STEMI) [8]. In a more recent work, we have shown
that circulating miR-499-5p may be a useful marker for early
discrimination between congestive heart failure and Non ST-
Elevation Myocardial Infarction (NSTEMI) in elderly patients
presenting to hospital with unclear symptoms [9].
In the search for diagnostic biomarkers of chest pain of
cardiac origin, circulating miRNAs have been previously
investigated in blood, serum, plasma, platelets, and peripheral
blood mononuclear cells (PBMC) in patients with both stable
and unstable angina [10]. However, the high heterogeneity in
study design, patient population, and miRNA source and
detection methods is likely to be responsible for the high
variability and poor overlap of the aberrant miRNA signatures
identified, making extrapolation of conclusive information
difficult.
The purpose of the present study was to search for
distinctive miRNA profiles in plasma of patients with
angiographically-documented troponin-negative CAD in
comparison to controls matched for cardiovascular risk factors.
The potential diagnostic significance of circulating miRNAs has
been challenged by ROC curve and hierarchical cluster




CAD Subjects.  The study was approved by the Ethical
Committee of Centro Cardiologico Monzino (CCM) IRCCS,
Milano, Italy. All subjects provided written informed consent at
the time of enrollment. Fifty-three patients affected by
angiographically documented CAD were enrolled for this study.
CAD was defined as at least one major epicardial vessel with
>70% stenosis, assessed by quantitative coronary
angiography. Subjects included in the study were both patients
with UA referred to the First Aid Department (duration of
symptoms from onset to hospital admission ≤ 24 hrs) and
patients affected by SA recruited from the Outpatient
Department. Angina pectoris was categorized as either stable
or unstable according to ACC/AHA guidelines [11,12]. In
particular, patients with SA had typical chest pain on exertion
associated with ST segment depression >1.0 mm on an
exercise test. UA was defined as chest pain occurring at rest or
minimal exertion, of new onset (within 1 month) or with a
worsening pattern (in frequency, intensity, or duration), without
evidence of myocardial necrosis based on the rise in cardiac
serum markers such as creatine kinase isoenzyme (CK)-MB
and troponin T or I.
Clinical history and medication records were also collected.
Exclusion criteria were: impaired left ventricular ejection
fraction ≤ 45%, congestive heart failure, chronic kidney or
hepatic disease, acute myocardial infarction, and malignant
disease.
Controls.  Twenty volunteers matched for sex, age, smoking
habit, hypertension, and diabetes and without history of CAD or
inflammatory disorders served as control group. All volunteers
provided written informed consent at the time of enrollment.
Samples Collection
Peripheral venous blood samples were collected in EDTA-
coated tubes (BD) and either processed immediately or stored
at 4°C for up to 24h. Previous analysis showed that the storage
method does not impact on miRNA detection [8]. Cell- and
platelet-free plasma was prepared following a 2 step
centrifugation protocol. After plasma separation from blood,
samples were centrifuged at 1.500 × g for 15’ at 4°C to remove
remaining cells and debris. The supernatant was centrifuged
again at 14.000 × g for 15’ at 4°C to obtain platelet-poor
plasma and, thereafter, aliquoted and stored at -80°C until use.
RNA extraction
Total RNA was extracted from 400 µl of plasma using 1 ml of
TRIzol reagent (Life Technologies), following a modified
protocol for liquid samples. Briefly, following phase separation,
RNA was precipitated by adding 30 μg of glycogen (Roche)
and 1 ml of isopropanol to the recovered aqueous phase. After
10’ at room temperature, RNA samples were pelleted 10’ at
12.000 × g, washed with 1 ml of ethanol 70%, and centrifuged
again 10’ at 12.000 × g. Supernatants were eliminated and,
after a 5’ drying step, pellets were resuspended in RNAse-free
water.
miRNAs expression analysis
TaqMan Human microRNA Card A Arrays version 2.0 (Life
Technologies) were used for expression screening of 367
miRNAs, conducted on 4 RNA samples randomly selected
from each group of subjects (SA, UA and Controls). Reverse
transcription (RT) and pre-amplification steps were performed
according to the manufacturer’s protocol, using a 7900HT Fast
Real-Time PCR System (Life Technologies). Screening results
were expressed as Ct (cycle threshold) levels and normalized
to the median Ct of each sample (ΔCt), so that all subsequent
calculations were independent from RNA amount added to the
PCR reaction. Relative expression was calculated using the
comparative Ct method (2-[Δ][Δ]Ct). All miRNAs detectable in
all 4 samples showing a Ct < 40 were considered as
Human Plasmatic miRNA Alteration by CAD
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expressed. To minimize the number of false positives, we
considered for the subsequent confirmation phase only those
miRNAs whose expression in CAD patients significantly
differed from the controls on average more than 2-folds. All
following steps were conducted by qRT-PCR using single
TaqMan microRNA assays (Life Technologies), accordingly to
manufacturer’s instructions. Since no RNA quantitation was
possible, the same volume of RNA solution (2 µl) was inputted
in each RT assay for technical consistency.
Profiling data analysis showed 4 potential normalizers that
exhibited strong expression in all samples: miR-15b, miR-16,
miR-17-5p, and miR-29. Among these, using a restricted cohort
of randomly selected patients and controls (n=10 for each
group), two miRNAs were identified as best potential
normalizers using the geNorm algorithm [13]: miR-16 and
miR-17-5p. After assessing that no discrepancies were
detectable by the usage of either miR-16 or miR-17-5p as
single normalizer (data not shown), we selected miR-16 as
internal calibrator, based on its persistent and stable
expression throughout all considered samples. The
confirmation step of the screening results was conducted on
the same samples used to identify the best internal normalizer,
and then the analysis was extended to all remaining samples
(24 for SA, 9 for UA and 10 for Controls).
Laboratory assays
Cardiac troponin I (cTnI), creatine kinase (CK) and MB
isoenzyme of creatine kinase (CK-MB) were measured using
the Access Immunoassay System (Beckman Coulter).
Triglycerides and total, LDL and HDL cholesterol were
measured using the UniCel DxC 600 (Beckman Coulter).
Statistical methods
Validated miRNAs expression data were analyzed using
GraphPad Prism version 5.03 for Windows (GraphPad
Software, San Diego, CA, www.graphpad.com) and reported
as mean ± standard error of the mean (SEM). Expression data
were tested for normal distribution using D’Agostino and
Pearson normality test and differences among groups were
compared using either One-way ANOVA or non-parametric
Kruskal-Wallis with Dunn’s post-hoc test, when appropriate.
Subjects’ clinical data were analyzed with SPSS/Win program
version 17.0 (SPSS, Chicago, IL) and reported as mean ±
standard deviation (SD). Differences among groups were
compared using One-way ANOVA or Student’s t-test for
continuous variables and χ2 test for categorical variables.
Receiver Operating Characteristic (ROC) curves were
calculated to estimate the area under the curve (AUC) for
selected miRNAs in relation to disease (SA and UA).
Hierarchical clustering was performed based on Euclidean
distance between the two CAD groups vs. controls with
complete linkage method and discriminant analysis was used
to calculate the percentage of cases correctly classified by
combination of selected miRNAs. Probability values lower than
0.05 were considered statistically significant. The reported p-
values were two-tailed in all calculations.
Results
Screening Phase
We enrolled a total of 53 consecutive CAD patients with
Stable or Unstable Angina. A cohort of 20 subjects matched for
sex, age, smoking habit, hypertension, and diabetes served as
Control group. An initial screening of 367 miRNAs was
conducted on plasma samples from 4 randomly allocated
subjects from each group. The characteristics of enrolled
patients and controls are summarized in Table 1. SA and UA
patients significantly differed only for the number of stents
implanted (0.9±1.0 vs. 1.6±0.8, respectively, p=0.019).
Out of the 367 miRNAs screened, 178 were detectable in all
subjects. By comparing the 3 cohorts of subjects, we selected
10 miRNAs which showed an average 2-fold change between
CAD patients and controls. There was no evidence of
differentially regulated miRNAs between SA and UA patients.
Confirmation step and analysis of expression
The confirmation step of the screening phase was conducted
on restricted cohorts of SA and UA patients and control
subjects (n=10 for each group). Three out of the 10 putatively
Table 1. Clinical characteristics of enrolled subjects.
 CONTROLS   STABLE   UNSTABLE  
 (n=20) (n=34) (n=19) p
Gender (% Males) 95 88.2 78.9 0.365
Age (mean ± st.dev.) 62.5 ± 2.1 60.0 ± 10.6 64.7 ± 11.8 0.871
Hypertension (%) 55.0 64.7 77.8 0.416
Smoker (%) 60.0 72.7 65.6 0.649




/ 44.1 50.0 0.654
β-blocker (%) / 61.8 61.1 0.892
ASA (%) / 44.1 50.0 0.562
ACE-inhibitor (%) / 32.4 33.3 0.708
Diuretic (%) / 5.9 11.1 0.256
Statin (%) / 58.8 38.9 0.214
Nitrates (%) / 44.1 44.4 0.805
Total cholesterol (mg/dL) / 214.2 ± 51.1 206.7 ± 51.3 0.491
LDL cholesterol (mg/dL) / 148.7 ± 79.9 168.1 ± 153.3 0.678
HDL cholesterol (mg/dL) / 55.3 ± 30.3 45.8 ± 12.0 0.194
Triglycerides / 158.3 ± 73.1 119.8 ± 78.7 0.105
n STENT / 0.9 ± 1.0 1.6 ± 0.8 0.039 *
n vessels (stenosis > 75%) / 1.9 ± 1.2 1.9 ± 1.1 0.841
CK-MB (ng/mL) / 4.0 ± 4.4 2.8 ± 2.9 0.267
CK (UI/L) / 116.2 ± 89.6 120.7 ± 105.7 0.961
TnI (ng/mL) / 0.04 ± 0.05 0.02 ± 0.01 0.122
All values are presented as mean ± standard deviation (St. dev.). Abbreviations:
AMI = Acute Myocardial Infarction; PCI = percutaneous coronary intervention;
CABG = coronary artery bypass graft; PTA = Percutaneous Transluminal
Angioplasty; ASA = acetylsalicylic acid; CK-MB = Creatine Kinase-MB; TnI =
Troponin I; * p<0.05.
doi: 10.1371/journal.pone.0080345.t001
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modulated miRNAs showed a statistically significant (p<0.05)
up-regulation: miR-337-5p, -433, and -485-3p. Conversely, the
other 7 miRNAs selected from the screening were not
confirmed as significant at this step. The discrepancies
between screening and validation results could be attributable
to the differences in detection and normalization methods and
in the sample sizes. The expression analysis was then
extended to all remaining patients and controls and this step
further uphold the significant positive regulation of miR-337-5p,
-433, and -485-3p. In particular, when compared to controls,
miR-337-5p (Figure 1A) showed a significant increase in the
SA group (9.4±4.4 folds, p=0.001), but not in UA subjects.
Conversely, miR-433 (Figure 1B) and miR-485-3p (Figure 1C)
showed a very strong positive modulation both in SA (9.6±2.1
and 42.4±19.5 folds, respectively, p<0.001 for both) and in UA
patients (4.6±1.3 and 29.7±17.8 folds, p=0.002 and p<0.001,
respectively), when compared to controls. Interestingly, none of
the 3 miRNAs showed statistically significant expression
differences between SA and UA patients.
Analysis of literature-selected miRNAs
In addition to the above screening-selected miRNAs, we
investigated by qRT-PCR the expression of a subset of
circulating miRNAs, previously demonstrated by us and others
to be involved in CAD [14] and STEMI [8]. In particular, we
analyzed the expression of CAD-related miR-17-5p, -92a, -126,
-133a, -145, -155, -199a, and -208a, and STEMI-related miR-1,
-122, -133a, -133b, -375, and -499-5p. Six of these miRNAs
showed an increase in both SA and in UA patients (Figure 1D
to 1L): miR-1 (31.2±6.5 in SA, 22.6±5.2 in UA, p<0.001 for
both; Figure 1D), miR-122 (5.7±1.6 in SA, 4.0±1.5 in UA,
p=0.040 and p=0.011, respectively; Figure 1E), miR-126
(15.4±2.4 in SA, 12.5±2.9 in UA, p<0.001 for both; Figure 1F),
miR-133a (18.0±5.0 in SA, 7.4±2.6 in UA, p<0.001 for both;
Figure 1G), miR-133b (21.0±7.5 in SA, 6.2±3.4 in UA, p=0.003
Figure 1.  Plasmatic miRNAs regulation by CAD in Stable and Unstable Angina patients.  Panels A to L. All investigated
miRNAs showed increased expression in CAD subjects, both in SA (yellow bars, 5.7–42.4 fold increase with the exception of
miR-145, not regulated) and UA (blue bars, 2.9–29.7 fold increase with the exception of miR-337-5p, not regulated) patients. Values
indicate fold changes (expressed as mean ± SEM) of each miRNA vs. its level in control healthy subjects (CTRLS, red bars),
arbitrarily set to 1. (*) indicates p≤0.05 vs. control; NS=not significant. Differences among groups were compared using either One-
way ANOVA or non-parametric Kruskal-Wallis with Dunn’s post-hoc test, when appropriate.
doi: 10.1371/journal.pone.0080345.g001
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and p<0.001, respectively; Figure 1H), and miR-199a (9.4±1.9
in SA, 16.9±6.1 in UA, p=0.001 and p=0.007, respectively;
Figure 1I). In contrast, miR-145 demonstrated a positive
regulation in UA patients only (2.9±1.3, p=0.002; Figure 1L).
Diagnostic potential of circulating miRNAs
To determine the predictive capacity of miRNAs identified
above, we performed ROC curve analyses. The most
predictive AUC values (>0.85) were obtained in SA patients,
when compared to Controls, for miR-1, -126, and -485-3p
(0.918, 0.929, and 0.851, respectively; Figure 2), although
good AUC values were obtained for almost all considered
miRNAs (Figure S1). Similarly, AUC values >0.85 were
observed in UA subjects for miR-1, -126, and -133a (0.920,
0.867, and 0.906, respectively; Figure 3), while all remaining
miRNAs showed AUC values <0.85 (Figure S2). Interestingly,
none of the considered miRNAs reached an acceptable AUC
value to differentiate SA from UA patients (Figure 4), ranging
from 0.404 (miR-145) to 0.678 (miR-337-5p).
In an attempt to identify a signature with diagnostic potential
resulting from a combination of miRNAs, we performed a
hierarchical cluster analysis on all miRNAs found regulated by
CAD. Figure 5 (and Figure S3) shows that the combined
expression of miR-1, -126, and -485-3p correctly classifies SA
patients vs. Controls with an efficiency of 90.2%. Similarly, the
combination of miR-1, -133a, and -126 presented 87.2%
efficiency in discriminating UA patients from control subjects
(Figure 5 and Figure S4). In contrast, the efficiency of CAD-
regulated circulating miRNAs to correctly differentiate SA from
UA subjects was not higher than 66% (see Figure 5).
Discussion
The main findings of this work are the evidences that: i)
specific plasmatic miRNA signatures may have the potential to
unveil with high efficiency (>85%) the presence of a significant
angiographically documented Stable (miR-1, miR-126,
miR-485-3p) or Unstable (miR-1, miR-126, miR133a) CAD vs.
Figure 2.  ROC curve analysis of CAD-miRNAs in Stable Angina patients and control subjects.  The figure depicts calculated
ROC curve and respective AUC values for miR-1, miR-126, and miR-485-3p, which exhibited good accuracy (AUC>0.85) in
differentiating Stable Angina (SA) patients from matched controls (C).
doi: 10.1371/journal.pone.0080345.g002
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matched Controls; ii) conversely, the ability of plasmatic
miRNAs to discriminate Stable from Unstable CAD is low.
MiRNAs have recently gained interest for their role in the
pathogenesis of cardiovascular disease, including
atherosclerosis and acute coronary syndromes [15]. In the
search for diagnostic and predictive biomarkers of CAD,
circulating miRNAs have been previously investigated in blood,
serum, plasma, platelets, and PBMC. A large number of
miRNAs have been found to be either up- or down-regulated in
patients with angiographically-documented significant Stable
and Unstable CAD compared with controls. However,
differences in study design, patient population, and,
particularly, miRNA sources, are likely to be responsible for the
high variability and poor overlap of the aberrant miRNA
signatures identified, thus making difficult to extrapolate
conclusive information. In particular, since miRNA profiles are
likely to be specific for the investigated blood components [10],
the starting material is crucial for the evaluation of the potential
of miRNAs as circulating biomarkers of CAD. In view of a
possible clinical transferability, we have isolated circulating
miRNAs from EDTA-plasma, given the sensitivity of the
TaqMan qPCR technique in these preparations [14,16].
Further, plasma allows the exclusion of the strong interference
of PMBC and platelets as sources of RNA, given the high
heterogeneity of miRNAs signatures previously identified in
these components [10]. To our knowledge, a previous study by
Fichtlscherer and coworkers [14] is the only one that
investigated the plasmatic levels of miRNAs from patients with
CAD. Thirty-six patients with stable angiographically-
documented CAD and 7 healthy controls served as derivation
cohort; results obtained were then prospectively tested in 14
negative controls and 31 patients. Circulating levels of
endothelial-enriched miR-126, miR-17, and miR-92a,
inflammation-associated miR-155 and muscle-enriched
miR-145 have been found significantly reduced in CAD
compared with controls. In contrast, cardiac-muscle-enriched
miR-133a and miR-208a showed a tendency for an increased
concentration in plasma, albeit not significant. Notably, there
are some important differences between Fichtlscherer’s study
and ours, which should be considered when comparing the
Figure 3.  ROC curve analysis of CAD-miRNAs in Unstable Angina patients and control subjects.  The figure depicts
calculated ROC curve and respective AUC values for miR-1, miR-126, and miR-133a, which exhibited good accuracy (AUC>0.85) in
differentiating Unstable Angina (UA) patients from matched controls (C).
doi: 10.1371/journal.pone.0080345.g003
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results. First, along with stable CAD patients, we have
prospectively enrolled a cohort of troponin-negative
angiographically-documented unstable patients. Secondly, we
have used a different normalization methodology that relies on
an internal normalizer instead of a spiked-in synthetic
exogenous miRNA (e.g. cel-miR-39). In our opinion, our
technique allows a more reliable identification of a suitable and
stable internal normalizer which compensates for the variability
of RNA amount in different samples. The alternative spike-in
method, more suited for normalization of differences in RNA
recovery, has intrinsic flaws, because it postulates that equal
volumes of plasma always contain the same amount of RNA.
Thus, the addition of a fixed amount of an exogenous synthetic
miRNA to variable amounts of total RNA may affect the final
miRNA quantification [17]. Finally and most importantly, we put
attention during the enrollment phase to match stable and
unstable patients for known cardiovascular risk factors and
pharmacological therapy, given the influence of these variables
on circulating miRNAs [18-21].
The discriminating power of selected and validated CAD-
related miRNAs was firstly assessed by means of ROC curve
analysis. We considered as highly discriminating AUC values
those above 0.85 [22]. MiR-1, miR-126, and miR-133a were
found to be highly predictive as potential single biomarker of
both stable and unstable angina. Interestingly, miR-1 and
miR-133a are co-transcribed and have been previously
extensively reported as associated to cardiovascular disease
[23]. Intriguingly, the plasmatic up-regulation of the
“endothelial-specific” miR-126 in presence of stable and
unstable angina may mirror a condition of endothelial
dysfunction occurring in the ischemic microcirculation during
chronic angina or acute coronary syndromes [24]. There is no
known relation between miR-485-3p expression and
cardiovascular disease.
It is noteworthy mentioning that, using our own normalization
technique, Sun and co-workers [25] recently reported the
decrease in plasmatic expression of miR-126 in CAD patients
with high low-density lipoprotein (LDL) cholesterol levels. In
contrast, the level of miR-126 was significantly increased when
Figure 4.  ROC curve analysis of CAD-miRNAs in Stable and Unstable Angina patients.  None of the investigated miRNAs
exhibited adequate accuracy in differentiating Stable (SA) from Unstable Angina (UA) patients: AUC values ranged between 0.404
(miR-145) and 0.678 (miR-337-5p).
doi: 10.1371/journal.pone.0080345.g004
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LDL cholesterol was high in patients who had risk factors for
CAD but did not have angiographically significant CAD.
Different from our study and in analogy with Fichtlscherer’s
study, however, patient enrolment was performed in a
population unmatched for age and major cardiovascular risk
factors, and patients without significant coronary stenosis
served as internal control group. These dissimilarities in
patient’s selection may at least partly explain the discrepancy
in results with our study.
MiRNA signatures in tissues and plasma have been shown
in oncologic patients to be able to efficiently predict disease
development and aggressiveness [26]. We have tested by
means of a hierarchical cluster analysis the hypothesis that
plasma miRNA signatures have the potential to unveil CAD.
The combination of cardiac-enriched miR-1, endothelial-
enriched miR-126, and miR-485-3p allowed the best
discrimination between SA patients and control donors with
good efficiency. The addition to this cluster of the cardiac-
enriched miR-133a with exclusion of miR-485-3p identified
successfully the presence of UA. These results may have a
relevant clinical read-out, given the unmet need of circulating
diagnostic biomarkers particularly in patients with stable angina
[27].
We failed to identify any circulating miRNA (either by ROC
curve or cluster analysis) with a satisfying potential in
discriminating SA from UA. The two signatures overlapped for
miR-1 and miR-126, and only differed for the presence of
miR-485-3p and miR-133a in SA and UA patients, respectively.
We and others have previously described an aberrant
circulating miRNAs regulation in presence of acute coronary
syndromes with Troponin dispersion [28]. Although it has been
suggested that unstable angina may entail a higher expression
of miRNA levels [29], SA and UA patients did not show a
markedly diverse circulating miRNA profile in our clinical
setting. It is worth to note that our UA population was carefully
documented for its troponin-negative profile.
Figure 5.  miRNA clusters efficiently differentiate SA and UA patients from Controls.  Hierarchical clustering demonstrated
that different miRNA “signatures” efficiently classify between matched controls (CTRLS) and CAD patients. The cluster composed
by miR-1 and miR-126 and miR-485-3p can be used to correctly classify SA patients from controls with 90.2% (yellow bar)
efficiency. Similarly the miR-1, miR-126 and miR-133a cluster can be used to correctly classify UA patients from controls with 87.2%
(red bar) efficiency. No signatures of miRNAs could be found to efficiently discriminate SA from UA patients with an accuracy > 66%
(miR-126 and miR-337-5p cluster, blue bar).
doi: 10.1371/journal.pone.0080345.g005
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A relevant issue is whether plasmatic signatures elicited in
angina are specific of troponin-negative CAD and not features
in common with MI. Interestingly, a data lookup from our
previous results in STEMI [8] and NSTEMI [9] showed that: i)
miR-1 and miR-133a were found increased both in angina and
MI patients; ii) miR-126 and miR-485-3p were up-regulated in
patients with angina only; iii) miR-499-5p was observed
specifically raised in MI patients only. A potential drawback of
the aforementioned comparison lies in the use of different
internal standards (miR-17-5p for MI and miR-16 for CAD
groups). Nonetheless, a retrospective analysis of published MI
plasma signatures showed that a restricted cohort of miRNAs
have been repeatedly found dysregulated (namely miR-1,
miR-133a, and miR-499-5p), irrespectively of the methodology
of normalization adopted (see Table S1), and this is in full
agreement with our observations. Notably, the aberrant
plasmatic expression of miR-499-5p emerges as the most
consistent marker of occurrence of heart damage [8,9,30,31].
Although the exact mechanism by which miRNAs are released
into the bloodstream upon myocardial ischemia is a matter of
investigation [32], this feature may be explained with a passive
release of this specific miRNA triggered by cardiomyocyte
death. Thus, mir-499-5p represents a potential discriminating
factor within plasma miRNA signatures in CAD between
Troponin-positive vs. negative coronary syndromes [23].
Confirmatory studies are warranted in the future to verify this
issue under standardized experimental settings.
The main limitation of this work is its single-center set-up
involving a limited number of patients. Multicenter large-scale
studies will be required to definitively assess the potential of
circulating miRNAs as diagnostic biomarkers of angina.
Further, our screening method allowed the detection of only
367 human miRNAs: we cannot exclude that other miRNAs not
present on our arrays may be modulated under the same
experimental conditions. This work should, thus, be regarded of
a proof-of-principle that specific circulating miRNAs may
discriminate CAD patients from matched controls and, as such,
have the potential to be used as reliable diagnostic biomarkers.
In conclusion, this work shows that plasmatic profiles of
miRNAs are capable to accurately identify the presence of
troponin-negative angiographically-documented CAD, causing
either SA or UA. Due to the high overlap of the signatures
pinpointed, the miRNAs discriminating power between SA and
UA was found to be low. Further studies should address with
larger population cohorts the potential utility of plasmatic
miRNAs as biomarkers of CAD, along with the mechanisms
underpinning their release in the bloodstream.
Supporting Information
Figure S1.  ROC curve analysis of CAD-miRNAs in Stable
Angina patients and control subjects presenting AUC
values <0.85. The figure depicts calculated ROC curve and
respective AUC values for miR-122, miR-133a, miR-133b,
miR-145, miR-199a, miR-337-5p, and miR-433, which
exhibited acceptable accuracy (0.72<AUC<0.85) in
differentiating Stable Angina (SA) patients from matched
controls (C).
(JPG)
Figure S2.  ROC curve analysis of CAD-miRNAs in
Unstable Angina patients and control subjects presenting
AUC values <0.85. The figure depicts calculated ROC curve
and respective AUC values for miR-122, miR-133b, miR-145,
miR-199a, miR-337-5p, miR-433 and miR-485-3p, which
exhibited acceptable accuracy (0.69<AUC<0.85) in
differentiating Unstable Angina (UA) patients from matched
controls (C).
(JPG)
Figure S3.  Hierarchical clustering of stable angina
patients and healthy controls using microRNA signatures.
The figure depicts a dendrogram representing unsupervised
classification of SA patients and control subjects basing on
combination of miR-1, miR-126, and miR-485-3p expression.
SA=Stable Angina, C=Controls.
(JPG)
Figure S4.  Hierarchical clustering of unstable angina
patients and healthy controls using microRNA signatures.
The figure depicts a dendrogram representing unsupervised
classification of SA patients and Control subjects basing on
combination of miR-1, miR-126, and miR-133a expression.
UA=Unstable Angina, C=Controls.
(JPG)
Table S1.  Analysis of previous works concerning
circulating miRNA regulation after Myocardial Infarction.
(DOCX)
Author Contributions
Conceived and designed the experiments: YD M. Carena MR
GM GIC FA SM M. Capogrossi GP. Performed the
experiments: YD M. Carena PD. Analyzed the data: YD M.
Carena LS FM BB PD MR GM GIC FA SM M. Capogrossi GP.
Wrote the manuscript: YD M. Carena LS FM BB PD MR GM
GIC FA SM M. Capogrossi GP.
Human Plasmatic miRNA Alteration by CAD
PLOS ONE | www.plosone.org 9 November 2013 | Volume 8 | Issue 11 | e80345
References
1. Lenfant C (2010) Chest pain of cardiac and noncardiac origin.
Metabolism 59 Suppl 1: S41-S46. doi:10.1016/j.metabol.2010.07.014.
PubMed: 20837193.
2. Pope JH, Aufderheide TP, Ruthazer R, Woolard RH, Feldman JA et al.
(2000) Missed diagnoses of acute cardiac ischemia in the emergency
department. N Engl J Med 342: 1163-1170. doi:10.1056/
NEJM200004203421603. PubMed: 10770981.
3. Shruti K, Shrey K, Vibha R (2001) Micro RNAs: tiny sequences with
enormous potential. Biochem Biophys Res Commun 407: 445-449.
Review. PubMed: 21419103.
4. Fichtlscherer S, Zeiher AM, Dimmeler S (2011) Circulating microRNAs:
biomarkers or mediators of cardiovascular diseases? Arterioscler
Thromb Vasc Biol 31: 2383-2390. Review. doi:10.1161/ATVBAHA.
111.226696. PubMed: 22011751.
5. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK et
al. (2011) MicroRNAs in body fluids--the mix of hormones and
biomarkers. Nat Rev Clin Oncol 8: 467-477. Review. doi:10.1038/
nrclinonc.2011.76. PubMed: 21647195.
6. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A et al. (2009)
Circulating microRNAs, potential biomarkers for drug-induced liver
injury. Proc Natl Acad Sci U S A 106: 4402-4407. doi:10.1073/pnas.
0813371106. PubMed: 19246379.
7. Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC et
al. (2010) MiR423-5p as a circulating biomarker for heart failure. Circ
Res 106: 1035-1039. doi:10.1161/CIRCRESAHA.110.218297.
PubMed: 20185794.
8. D'Alessandra Y, Devanna P, Limana F, Straino S, Di Carlo A et al.
(2010) Circulating microRNAs are new and sensitive biomarkers of
myocardial infarction. Eur Heart J 31: 2765-2773. doi:10.1093/
eurheartj/ehq167. PubMed: 20534597.
9. Olivieri F, Antonicelli R, Lorenzi M, D'Alessandra Y, Lazzarini R et al.
(2013) Diagnostic potential of circulating miR-499-5p in elderly patients
with acute non ST-elevation myocardial infarction. Int J Cardiol 167:
531-536. doi:10.1016/j.ijcard.2012.01.075. PubMed: 22330002.
10. Tijsen AJ, Pinto YM, Creemers EE (2012) Circulating microRNAs as
diagnostic biomarkers for cardiovascular diseases. Am J Physiol Heart
Circ Physiol 303: H1085-H1095. doi:10.1152/ajpheart.00191.2012.
PubMed: 22942181.
11. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC et al. (2012)
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the
diagnosis and management of patients with stable ischemic heart
disease: a report of the American College of Cardiology Foundation/
American Heart Association Task Force on Practice Guidelines, and
the American College of Physicians, American Association for Thoracic
Surgery, Preventive Cardiovascular Nurses Association, Society for
Cardiovascular Angiography and Interventions, and Society of Thoracic
Surgeons. J Am Coll Cardiol 60: e44-e164. doi:10.1016/j.jacc.
2012.08.172. PubMed: 23182125.
12. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD et al.
(2002) ACC/AHA guideline update for the management of patients with
unstable angina and non-ST-segment elevation myocardial
infarction--2002: summary article: a report of the American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines (Committee on the Management of Patients With Unstable
Angina). Circulation106: 1893-1900. doi:10.1161/01.CIR.
0000037106.76139.53. PubMed: 12356647.
13. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N et al.
(2002) Accurate normalization of real-time quantitative RT-PCR data by
geometric averaging of multiple internal control genes. Genome Biol 3:
RESEARCH0034. PubMed: 12184808.
14. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A et al. (2010)
Circulating microRNAs in patients with coronary artery disease. Circ
Res 107: 677-684. doi:10.1161/CIRCRESAHA.109.215566. PubMed:
20595655.
15. Papageorgiou N, Tousoulis D, Androulakis E, Siasos G, Briasoulis A et
al. (2012) The role of microRNAs in cardiovascular disease. Curr Med
Chem 19: 2605-2610. Review. doi:10.2174/092986712800493048.
PubMed: 22489721.
16. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK et al. (2008)
Circulating microRNAs as stable blood-based markers for cancer
detection. Proc Natl Acad Sci U S A 105: 10513-10518. doi:10.1073/
pnas.0804549105. PubMed: 18663219.
17. van Empel VP, De Windt LJ, da Costa Martins PA (2012) Circulating
miRNAs: reflecting or affecting cardiovascular disease? Curr Hypertens
Rep 14: 498-509. doi:10.1007/s11906-012-0310-7. PubMed:
22996205.
18. Ortega FJ, Mercader JM, Catalán V, Moreno-Navarrete JM, Pueyo N et
al. (2013) Targeting the circulating microRNA signature of obesity. Clin
Chem 59: 781-792. doi:10.1373/clinchem.2012.195776. PubMed:
23396142.
19. Li S, Zhu J, Zhang W, Chen Y, Zhang K et al. (2011) Signature
microRNA expression profile of essential hypertension and its novel link
to human cytomegalovirus infection. Circulation 124: 175-184. doi:
10.1161/CIR.0b013e31822c95c8. PubMed: 21690488.
20. Gao W, He HW, Wang ZM, Zhao H, Lian XQ et al. (2012) Plasma
levels of lipometabolism-related miR-122 and miR-370 are increased in
patients with hyperlipidemia and associated with coronary artery
disease. Lipids Health Dis 11: 55. doi:10.1186/1476-511X-11-55.
PubMed: 22587332.
21. Weber M, Baker MB, Patel RS, Quyyumi AA, Bao G et al. (2011)
MicroRNA Expression Profile in CAD Patients and the Impact of ACEI/
ARB. Cardiol. Res Pract: 2011:532915
22. Nikas JB, Low WC (2011) ROC-supervised principal component
analysis in connection with the diagnosis of diseases. Am J Transl Res
3: 180-196. PubMed: 21416060.
23. D'Alessandra Y, Pompilio G, Capogrossi MC (2012) MicroRNAs and
myocardial infarction. Curr Opin Cardiol 27: 228-235. doi:10.1097/HCO.
0b013e3283522052. PubMed: 22476028.
24. Stępień E, Stankiewicz E, Zalewski J, Godlewski J, Zmudka K et al.
(2012) Number of microparticles generated during acute myocardial
infarction and stable angina correlates with platelet activation. Arch
Med Res 43: 31-35. doi:10.1016/j.arcmed.2012.01.006. PubMed:
22306248.
25. Sun X, Zhang M, Sanagawa A, Mori C, Ito S et al. (2012) Circulating
microRNA-126 in patients with coronary artery disease: correlation with
LDL cholesterol. Thromb J 10: 16. doi:10.1186/1477-9560-10-16.
PubMed: 22925274.
26. Boeri M, Verri C, Conte D, Roz L, Modena P et al. (2011) MicroRNA
signatures in tissues and plasma predict development and prognosis of
computed tomography detected lung cancer. Proc Natl Acad Sci U S A
108: 3713-3718. doi:10.1073/pnas.1100048108. PubMed: 21300873.
27. Henderson RA, Timmis AD (2011) Almanac 2011: stable coronary
artery disease. An editorial overview of selected research that has
driven recent advances in clinical cardiology. Heart 97: 1552-1559. doi:
10.1136/heartjnl-2011-300896. PubMed: 21900584.
28. Fasanaro P, D'Alessandra Y, Magenta A, Pompilio G, Capogrossi MC
(2013) MicroRNAs: promising biomarkers and therapeutic targets of
acute myocardial ischemia. Curr Vasc Pharmacol (. (2013)) PubMed:
23713865.
29. Latsios G, Tousoulis D, Androulakis E, Papageorgiou N, Synetos A et
al. (2013) miRNAs In The Diagnosis And Treatment Of Unstable
Angina. Curr Top Med Chem (In press).
30. Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y et al.
(2010) Circulating MicroRNA-208b and MicroRNA-499 reflect
myocardial damage in cardiovascular disease. Circ Cardiovasc Genet
3: 499-506. doi:10.1161/CIRCGENETICS.110.957415. PubMed:
20921333.
31. Gidlöf O, Andersson P, van der Pals J, Götberg M, Erlinge D (2011)
Cardiospecific microRNA plasma levels correlate with troponin and
cardiac function in patients with ST elevation myocardial infarction, are
selectively dependent on renal elimination, and can be detected in
urine samples. Cardiology 118: 217-226. doi:10.1159/000328869.
PubMed: 21701171.
32. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y et al. (2010)
Secretory mechanisms and intercellular transfer of microRNAs in living
cells. J Biol Chem 285: 17442-17452. doi:10.1074/jbc.M110.107821.
PubMed: 20353945.
Human Plasmatic miRNA Alteration by CAD
PLOS ONE | www.plosone.org 10 November 2013 | Volume 8 | Issue 11 | e80345
